Chat with us, powered by LiveChat


Global Gabapentin Market Report


Global Gabapentin Market by Dosage Form (Tablet, Capsule, and Oral Solution), Type (Generic and Branded), Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032


Pages: 280

Aug 2023

Gabapentin Overview

A drug called gabapentin is used to treat nerve pain. It functions in several ways to stop epileptic seizures and prevent pain signals from entering the brain. A medication called gabapentin (also known as Neurontin, Gralise, or Horizant) is used to treat partial seizures, shingles-related nerve discomfort, and restless leg syndrome. It affects the nerves' and brain's chemical messengers. The drug gabapentin belongs to the class of drugs known as anticonvulsants.

Global Gabapentin Market Analysis

The global gabapentin market size was $2.0 billion in 2022 and is predicted to grow with a CAGR of 5.5%, by generating a revenue of $3.4 billion by 2032.

COVID-19 Impact on Global Gabapentin Market

The pandemic has had an effect on the global pharmaceutical supply chain, resulting in sporadic delays or gabapentin shortages. These changes might have temporarily changed the market's supply and possibly restricted patient access.

Neuropathic pain is one example of chronic pain that needs continuing therapy. Even after the pandemic, there will likely still be a demand for gabapentin as people look for treatment from these problems. The persistent demand for gabapentin may be influenced by the increased attention given to and knowledge of pain control during COVID-19.

Neuropathic Pain Management to Drive the Market Growth

For the treatment of neuropathic pain brought on by illnesses such diabetic neuropathy, post-herpetic neuralgia, and peripheral neuropathy, gabapentin has received approval. The need for gabapentin as a pain relief alternative rises as the frequency of these conditions rises. The investigation of gabapentin's efficiency for these off-label purposes boosts market demand for the drug. The availability of generic alternatives has boosted market competitiveness and supported its expansion.

Side Effects and Safety Concerns to Restrain Market Growth

Potential adverse effects of gabapentin include drowsiness, dizziness, exhaustion, issues with coordination, and weight gain. Some people might develop bad reactions or side effects that are more severe. Patient compliance and the general market demand may be impacted by safety worries and potential dangers related to the long-term use of gabapentin. Because of the possibility of abuse or misuse, gabapentin is regulated in several areas. Such regulations may have an effect on the accessibility and availability of gabapentin, thus limiting the market's expansion. Although gabapentin works well for some diseases, there are other options for treatment. Pregabalin and a few other drugs may be prescribed for neuropathic pain and epilepsy, giving patients other options and perhaps impacting the growth of the gabapentin market.

Technological Advancements to Drive Excellent Opportunities

Beyond its current approved applications, gabapentin has demonstrated potential benefit for a number of illnesses. The creation of Gabapentin extended-release formulations offers chances to enhance patient comfort and adherence. Extended-release formulations enable less frequent dosage and could offer improved symptom control, increasing patient satisfaction and market demand. In developing nations where there may be a rise in the demand for therapies for epilepsy and neuropathic pain, the gabapentin industry still has room for expansion. The need for gabapentin may rise as these areas' healthcare systems develop and people have greater access to healthcare services.

Global Gabapentin Market Share, by Dosage Form, 2022

The capsule sub-segment accounted for the highest share in 2022. Typically, capsules are primarily used to treat neuropathic pain and epilepsy. Both epilepsy and neuropathic pain are illnesses that significantly impact people worldwide. There may be a rise in demand for Gabapentin capsules as awareness of these illnesses rises.

Global Gabapentin Market Share, by Type, 2022

The generic sector accounted for the highest market size in 2022. The branded Gabapentin product's patent expiration opens the market to the introduction of generic equivalents. Generic manufacturers are able to create and sell their own brands of gabapentin, usually for less money than the brand-name equivalent. This heightened rivalry may result in lower costs and greater market accessibility. In general, generic Gabapentin drugs are less expensive than their branded counterparts. They are a desirable option for patients and healthcare professionals due to their lower cost. The demand for generic Gabapentin may consequently rise, fueling market expansion.

Global Gabapentin Market Share, by Application, 2022

The epilepsy sector accounted for the highest market size in 2022. Recurrent seizures are a neurological disease known as epilepsy. The choice of Gabapentin on the epilepsy market may depend on patient preferences, which may include elements like simplicity of administration (such as capsule formulations), dose frequency, and adherence to therapy. Patients could favour medications that are practical and simple to work into everyday habits. The epilepsy market may be considerably impacted by the introduction of generic Gabapentin. When a branded Gabapentin product's patent runs out, generic producers can enter the market and provide less expensive substitutes. For epilepsy patients, generic competition can improve market accessibility and pricing. Its demand is influenced by successful patient outcomes.

Global Gabapentin Market Share, by Distribution Channel, 2022

The hospital pharmacy sector accounted for the highest market size in 2022. Hospital pharmacies often adhere to treatment protocols and formularies that offer advice on how to use medications. Hospital pharmacists are likely to write prescriptions for and dispense Gabapentin if it is on the hospital formulary and approved for specific conditions. In addition to epilepsy, gabapentin may also be utilised in hospital settings for neuropathic pain, postoperative pain, and supplementary therapy for psychiatric problems. The frequency of these indications and the particular requirements of the patient group being treated can have an impact on the demand for Gabapentin in hospital pharmacies.

Global Gabapentin Market Share, by Region, 2022

North America held the highest share in the gabapentin market in 2022. The main indications for Gabapentin are epilepsy and neuropathic pain, both of which are rather common disorders in North America. Regulatory aspects influence the gabapentin market in North America. The dynamics of the gabapentin market may be impacted by any modifications to laws or standards governing its use. Non-opioid pain management options are being emphasised more due to the opioid issue in North America. Due to its success in treating neuropathic pain, gabapentin has grown in demand as a non-opioid alternative, contributing to the expansion of its market in the area.

Competitive Scenario in the Global Gabapentin Market

Product development and geographic expansion are major strategies in the highly competitive global market.

Some of the leading gabapentin market players are Zydus Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC, Cipla USA, Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., BP Pharmaceuticals Laboratories Company, Aurobindo Pharma., and Amneal Pharmaceuticals LLC.




  Historical Market Estimations


  Base Year for Market Estimation


  Forecast Timeline for Market Projection


  Geographical Scope

  North America, Europe, Asia-Pacific, and      LAMEA

  Segmentation by Dosage Form

  • Tablet
  • Capsule
  • Oral Solution

  Segmentation by Type

  • Generic
  • Branded

  Segmentation by Application

  • Epilepsy
  • Neuropathic Pain
  • Restless Legs Syndrome
  • Others

  Segmentation by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

  Key Companies Profiled

  • Zydus Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Ascend Laboratories, LLC
  • Cipla USA, Inc.
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BP Pharmaceuticals Laboratories Company
  • Aurobindo Pharma.
  • Amneal Pharmaceuticals LLC.

Frequently Asked Questions

A. The size of the gabapentin market was over $2.0 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.5% during the forecast period.

A. Cipla USA, Inc. and Apotex Inc. are some of the key players in the global Gabapentin market.

A. The Asia-Pacific region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Product development and geographic expansion are the two key strategies opted by the operating companies in this market.

A. Cipla USA, Inc. and Apotex Inc. are the companies investing more on R&D activities for developing new products and technologies.

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed